Status regarding Novo Nordisk's holding of own shares
In continuation of the company's announcement dated 29 January 2009
concerning Novo Nordisk's share repurchase programme, and pursuant to
Section 29 of the Danish Securities Trading Act, this is to report
that as of today, Novo Nordisk A/S (NYSE:NVO) and its wholly-owned
affiliates own more than 5% of the total share capital in Novo
Nordisk A/S.
As per 2 June, Novo Nordisk A/S and its wholly-owned affiliates own
31,741,925 of its own B shares of DKK 1, corresponding to a total
nominal value of DKK 31,741,925 or 5.0% of the total share capital.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,900
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 31 / 2009
